Systematic Review

Published on 11 Nov 2024

The current state and trends of immunotherapy research in lung cancer: a review and bibliometric analysis

in Cancer Molecular Targets and Therapeutics

Yun-Hua Zheng
Li Chen
Xiang Liu
Rong-Hui Li
Hai-Bo Lei
Guang-Hui Chen

Frontiers in Oncology

doi 10.3389/fonc.2024.1428307

265 views

Review

Accepted on 08 Nov 2024

Potential Urinary Volatile Organic Compounds as Screening Markers in Cancer -A Review

in Cancer Molecular Targets and Therapeutics

Alexander Goertzen
Biniam Kidane
Nasser Ahmed
Michel Aliani

Frontiers in Oncology

doi 10.3389/fonc.2024.1448760

102 views

Original Research

Published on 08 Nov 2024

Characterization of the function and clinical value of ERCC family genes in lung adenocarcinoma

in Cancer Molecular Targets and Therapeutics

Zhimin Lu

Frontiers in Oncology

doi 10.3389/fonc.2024.1476100

223 views

Review

Accepted on 06 Nov 2024

Crosstalk between lactate and tumor-associated immune cells: clinical relevance and insight

in Cancer Molecular Targets and Therapeutics

Kemin Sun
Ye Shen
Xiang Xiao
Hao Xu
Ming Li
Quanli Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1506849

Original Research

Published on 06 Nov 2024

Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study

in Cancer Molecular Targets and Therapeutics

Meiling Zhang
Li Wang
Qian Wang
Jiu Yang
Wei Peng
Xiaoyou Li
Meiqi Shi
Kaihua Lu

Frontiers in Oncology

doi 10.3389/fonc.2024.1441025

528 views

Original Research

Accepted on 04 Nov 2024

Comprehensive Prognostic Gene Identification and Functional Characterization of GRAMD1A in Wilms Tumor: Development of Risk Prediction Models and Therapeutic Implications

in Cancer Molecular Targets and Therapeutics

Qiang Zeng
Junfeng Tao
Lilu Qin
Yong Zeng
Zhong Liu
Mingxian Xu
Linshan Zeng

Frontiers in Oncology

doi 10.3389/fonc.2024.1501718

Original Research

Accepted on 04 Nov 2024

Metabolomics and Network pharmacology guided analysis of TNF-α expression by Argemone Mexicana (Linn) targeting NF-kB signaling pathway in cancer cell lines

in Cancer Molecular Targets and Therapeutics

Sunanda Kulshrestha
Anjana Goel
Subhadip Banerjee
Rohit Sharma
Mohammad Rashid Khan
Kow-Tong Chen

Frontiers in Oncology

doi 10.3389/fonc.2024.1502819

Original Research

Accepted on 29 Oct 2024

Estrogenized HSA induced high-affinity autoantibodies in breast cancer -Novel biomarker for early detection Running Head: Estrogenized HSA autoantibodies in breast cancer

in Cancer Molecular Targets and Therapeutics

Subuhi Sherwani
Mohd Wajid Ali Khan
Wahid Ali Khan
Saravanan Rajendrasozhan
Khalid Al-motair
Hamda Khan
Saheem Ahmad

Frontiers in Oncology

doi 10.3389/fonc.2024.1493320

Case Report

Published on 28 Oct 2024

Response to furmonertinib in a patient with non-small cell lung cancer harboring HER2 exon 21 insertion mutation: a case report

in Cancer Molecular Targets and Therapeutics

Chunxiao Ni
Ling Zhang
Xin Yu
Yu Pang

Frontiers in Oncology

doi 10.3389/fonc.2024.1440379

512 views

Original Research

Published on 24 Oct 2024

Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway

in Cancer Molecular Targets and Therapeutics

Xiao Li
Mengna Cui
Long Xu
Qie Guo

Frontiers in Oncology

doi 10.3389/fonc.2024.1483660

992 views

Review

Published on 24 Oct 2024

Role of non-coding RNA in exosomes for the diagnosis and treatment of osteosarcoma

in Cancer Molecular Targets and Therapeutics

Xin Liu
Yaling Wang
Chenwen Wang
Xinyuan Wang
Gangqiang Tang
Zhou Xiong
Wei Zhou

Frontiers in Oncology

doi 10.3389/fonc.2024.1469833

417 views

Original Research

Accepted on 23 Oct 2024

EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer

in Cancer Molecular Targets and Therapeutics

Ruifang Sun
Qianqian Yu
Chen Lin
Long Zhang
Yilu Zhou
Runzhe Sun
Yongsheng Meng
Ningning Yao
Haizhen Wang
Feilin Cao

Frontiers in Oncology

doi 10.3389/fonc.2024.1433033

103 views

Original Research

Published on 18 Oct 2024

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion

in Cancer Molecular Targets and Therapeutics

Lisa A. King
Milon de Jong
Myrthe Veth
David Lutje Hulsik
Parsa Yousefi
Victoria Iglesias-Guimarais
Pauline M. van Helden
Tanja D. de Gruijl
Hans J. van der Vliet

Frontiers in Oncology

doi 10.3389/fonc.2024.1474007

933 views

Opinion

Published on 18 Oct 2024

The novel role of MDM2 in the diagnosis and treatment of dedifferentiated liposarcoma

in Cancer Molecular Targets and Therapeutics

Jiro Ichikawa
Tomonori Kawasaki
Kojiro Onohara
Satoshi Kanno
Masanori Wako
Satoshi Ochiai
Kaoru Aoki
Hirotaka Haro

Frontiers in Oncology

doi 10.3389/fonc.2024.1466399

297 views

Correction

Published on 17 Oct 2024

Corrigendum: Radiosynthesis and in-vitro identification of a molecular probe 131I-FAPI targeting cancer-associated fibroblasts

in Cancer Molecular Targets and Therapeutics

Yaxin Tian
Yanghongyan Jiang
Ping Ma
Xiaowei Ma
Liang Du
Fengkui Wang
Xiaodong Yu

Frontiers in Oncology

doi 10.3389/fonc.2024.1501235

236 views

Brief Research Report

Accepted on 16 Oct 2024

Targeted transcriptomic analysis of well-differentiated and dedifferentiated liposarcoma reveals multiple dysregulated pathways including glucose metabolism, TGF-β, and HIF-1 signaling

in Cancer Molecular Targets and Therapeutics

Ashley Patton
Natalie Horn
Puja Upadhaya
Patricia Sarchet
Raphael Pollock
Steve Oghumu
Obiajulu Hans Iwenofu

Frontiers in Oncology

doi 10.3389/fonc.2024.1456071

Navigation group

Articles

The current state and trends of immunotherapy research in lung cancer: a review and bibliometric analysis

Potential Urinary Volatile Organic Compounds as Screening Markers in Cancer -A Review

Characterization of the function and clinical value of ERCC family genes in lung adenocarcinoma

Crosstalk between lactate and tumor-associated immune cells: clinical relevance and insight

Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study

Comprehensive Prognostic Gene Identification and Functional Characterization of GRAMD1A in Wilms Tumor: Development of Risk Prediction Models and Therapeutic Implications

Metabolomics and Network pharmacology guided analysis of TNF-α expression by Argemone Mexicana (Linn) targeting NF-kB signaling pathway in cancer cell lines

Estrogenized HSA induced high-affinity autoantibodies in breast cancer -Novel biomarker for early detection Running Head: Estrogenized HSA autoantibodies in breast cancer

Response to furmonertinib in a patient with non-small cell lung cancer harboring HER2 exon 21 insertion mutation: a case report

Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway

Role of non-coding RNA in exosomes for the diagnosis and treatment of osteosarcoma

EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion

The novel role of MDM2 in the diagnosis and treatment of dedifferentiated liposarcoma

Corrigendum: Radiosynthesis and in-vitro identification of a molecular probe 131I-FAPI targeting cancer-associated fibroblasts

Targeted transcriptomic analysis of well-differentiated and dedifferentiated liposarcoma reveals multiple dysregulated pathways including glucose metabolism, TGF-β, and HIF-1 signaling